Oramed Pharmaceuticals Inc. (ORMP) Income Statement
ORMP 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsORMP revenue and net income
Where ORMP's revenue goes
2025Each bar shows an amount and its share of revenue. ORMP kept 3,202.5% of revenue as net income.
ORMP profit margins
ORMP growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | −9.6% | −5.9% | — |
| Gross profit | — | −83.1% | −65.6% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ORMP quarterly EPS vs estimates
Oramed Pharmaceuticals beat the analyst EPS estimate in 3 of the last 7 quarters. Next report: November 12, 2026 (estimate $0.43).
ORMP income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $0 | $1.3M | $2.7M | $2.7M | $2.7M | $2.7M | $2.4M | $2.5M | $641,000 |
| Cost of revenue | $2.0M | $193,000 | $0 | $0 | $0 | $90,000 | $90,000 | $86,000 | $187,000 | $490,000 |
| Gross profit | $13,000 | −$193,000 | $1.3M | $2.7M | $2.7M | $2.7M | $2.6M | $2.4M | $2.3M | $151,000 |
| Research & development | $6.4M | $6.3M | $9.0M | $27.6M | $21.0M | $10.2M | $13.5M | $12.0M | $10.3M | $7.7M |
| Sales, general & admin | $8.7M | $6.5M | $8.4M | $15.7M | $5.9M | $4.2M | $3.7M | $4.1M | $2.8M | $2.5M |
| Total operating expenses | $15.1M | $12.8M | $17.1M | $43.3M | $26.9M | $14.5M | $17.2M | $16.1M | $13.0M | $10.2M |
| Operating income | −$15.1M | −$12.8M | −$15.8M | −$40.6M | −$24.2M | −$11.8M | −$14.6M | −$13.5M | −$10.8M | −$10.0M |
| Interest income | $2.4M | $5.0M | $8.0M | $3.6M | $347,000 | $690,000 | — | — | — | — |
| Interest expense | $0 | $853,000 | $3.6M | $2.9M | $6,000 | — | $126,000 | $6,000 | $6,000 | $11,000 |
| Income before taxes | $75.3M | −$15.9M | $5.1M | −$37.7M | −$23.0M | −$11.5M | −$14.1M | −$12.7M | −$10.1M | −$9.6M |
| Income taxes | $11.3M | $3.2M | — | $100,000 | −$2.9M | $192,000 | $300,000 | −$800,000 | $400,000 | $1.3M |
| Net income | $64.0M | −$19.1M | $5.5M | −$37.8M | −$22.2M | −$11.5M | −$14.4M | −$12.7M | −$10.5M | −$11.0M |
| EBITDA | $75.4M | −$14.9M | $7.3M | −$40.5M | −$24.1M | −$11.8M | −$14.2M | −$13.5M | −$10.8M | −$10.0M |
| EPS (diluted) | $1.50 | −$0.48 | $0.14 | −$0.94 | −$0.77 | −$0.66 | −$0.72 | −$0.93 | −$0.77 | −$0.86 |
| Gross margin | 0.7% | — | 100.0% | 100.0% | 100.0% | 100.0% | 96.7% | 96.5% | 92.4% | 23.6% |
| Operating margin | −754.4% | — | −1,176.8% | −1,502.0% | −896.2% | −433.8% | −541.3% | −552.3% | −438.6% | −1,561.6% |
| Net margin | 3,202.5% | — | 412.3% | −1,397.1% | −822.7% | −424.8% | −531.1% | −519.7% | −426.7% | −1,710.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $2.0M | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $30,000 | $30,000 | $31,000 | $30,000 | $2.0M | $31,000 | $0 | $0 | $0 | $53,000 | — |
| Gross profit | $0 | −$30,000 | −$30,000 | −$31,000 | −$30,000 | $13,000 | −$31,000 | −$52,000 | −$54,000 | −$56,000 | −$53,000 | — |
| Research & development | $0 | $1.6M | $2.0M | $1.2M | $1.0M | $2.2M | $1.5M | $2.2M | $1.4M | $1.2M | $1.7M | $957,000 |
| Sales, general & admin | $2.8M | $2.1M | $3.7M | $1.3M | $1.5M | $2.3M | $2.1M | $847,000 | $1.7M | $1.8M | $2.1M | $2.6M |
| Total operating expenses | $2.8M | $3.7M | $5.6M | $2.4M | $2.5M | $4.5M | $3.6M | $3.1M | $3.1M | $3.0M | $3.8M | $2.9M |
| Operating income | −$2.8M | −$3.7M | −$5.7M | −$2.4M | −$2.5M | −$4.5M | −$3.6M | −$3.1M | −$3.1M | −$3.0M | −$3.9M | −$2.9M |
| Interest income | $103.7M | $276,000 | — | — | $15.4M | $647,000 | $1.1M | — | $14.2M | $5.1M | $3.5M | $435,000 |
| Interest expense | — | — | $337,000 | $0 | $0 | $2.6M | $15.4M | $15.4M | $261,000 | $592,000 | $1.2M | $826,000 |
| Income before taxes | $101.6M | $49.4M | $9.8M | $59.5M | $13.1M | −$7.1M | −$9.8M | −$18.5M | $10.8M | $1.5M | $13.3M | −$3.3M |
| Income taxes | $23.4M | $11.1M | −$212,000 | $11.1M | −$126,000 | $584,000 | $416,000 | $1.1M | $1.6M | — | — | $373,000 |
| Net income | $78.2M | $38.3M | $10.0M | $48.4M | $13.3M | −$7.6M | −$10.2M | −$19.6M | $9.2M | $1.5M | $13.3M | −$3.2M |
| EBITDA | $101.6M | −$3.6M | −$5.6M | $59.5M | $13.2M | −$4.5M | −$3.6M | −$18.5M | $11.2M | $2.2M | −$3.8M | −$2.4M |
| EPS (diluted) | −$0.09 | $0.91 | $0.25 | $1.13 | $0.31 | −$0.19 | −$0.26 | −$0.48 | $0.22 | $0.04 | $0.33 | −$0.08 |
| Gross margin | — | — | — | — | — | 0.7% | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | −225.0% | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | −382.1% | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ORMP's financial statements (latest annual report filed March 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ORMP financial results
In fiscal year 2025 (ended December 31, 2025), Oramed Pharmaceuticals reported revenue of $2.0 million. It had net income of $64.0 million, a net profit margin of 3,202.5%. Diluted earnings per share came to $1.50. Over five years revenue grew at an average rate of −5.9% a year.
See the ORMP stock overview for the latest quote and news, or the ORMP chart for price history and technical indicators.
ORMP income statement FAQ
What is Oramed Pharmaceuticals's annual revenue?
Oramed Pharmaceuticals reported total revenue of $2.0 million for fiscal year 2025, which ended on December 31, 2025.
Is Oramed Pharmaceuticals profitable?
Yes. Oramed Pharmaceuticals reported net income of $64.0 million in fiscal 2025, a net profit margin of 3,202.5%; its operating margin was −754.4%.
What is Oramed Pharmaceuticals's gross margin?
Oramed Pharmaceuticals's gross margin was 0.7% in fiscal 2025: for every $100 of revenue, Oramed Pharmaceuticals kept $1 after the direct cost of its products and services.
How much does Oramed Pharmaceuticals spend on research and development?
Oramed Pharmaceuticals spent $6.4 million on research and development in fiscal 2025, 319.1% of revenue.
How fast is Oramed Pharmaceuticals growing?
Revenue grew −5.9% a year on average over the last five fiscal years, from $2.7 million to $2.0 million.
What are Oramed Pharmaceuticals's earnings per share?
Oramed Pharmaceuticals earned $1.50 per diluted share in fiscal 2025, compared with $-0.48 a year earlier.
When will Oramed Pharmaceuticals report its next earnings?
Oramed Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes.
When does Oramed Pharmaceuticals's fiscal year end?
Oramed Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 26, 2026.